FDA Analysis Finds Evidence of Kratom’s Opioid Properties
February 8, 2018
(Managed Care Magazine) – A scientific analysis found stronger evidence that compounds in kratom have opioid properties, according to FDA Commissioner Scott Gottlieb, MD, who added that the agency has now received 44 reports of deaths linked to the Asian plant. In November 2017, the FDA warned the public not to use kratom (Mitragyna speciose), which grows naturally in Thailand, Malaysia, Indonesia, and Papua New Guinea. The agency said the plant appeared to expose users to the risks of addiction, abuse, and dependence.